Clinical Trial Update: A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating dapagliflozin on renal outcomes and cardiovascular mortality in chronic kidney disease completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Kidney Disease | Phase 3 | Status: COMPLETED | Results posted: 2021-07-07